Karen Cui

Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer

Talia Golan, Pascal Hammel, Michele Reni et al. · New England Journal of Medicine · 2019 · 2.1K citations · Full text

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 404 citations · Full text

Breast Oncology, Overall Survival, Medicine +7

Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors.

Yiping Wu, Karen Cui, Keiko Miyoshi et al. · PubMed · 2003 · 201 citations

Breast Oncology, Lid Mice, Mammary Tumors +19

Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Hedy L. Kindler, Pascal Hammel, Michele Reni et al. · Journal of Clinical Oncology · 2022 · 200 citations · Full text

Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.

Talia Golan, Pascal Hammel, Michele Reni et al. · Journal of Clinical Oncology · 2021 · 78 citations

Maintenance O, Surgical Oncology, Cancer Management +18